250 related articles for article (PubMed ID: 25146483)
61. Stabilization by host cell components and Mg2+ of the neutralization epitopes of poliovirus.
Rombaut B; Vrijsen R; Boeyé A
J Gen Virol; 1985 Feb; 66 ( Pt 2)():303-7. PubMed ID: 2578552
[TBL] [Abstract][Full Text] [Related]
62. Antigenic characterization of poliovirus type 3 using monoclonal antibodies.
Ferguson M; Minor PD; Magrath DI; Spitz M; Schild GC
Rev Infect Dis; 1984; 6 Suppl 2():S510-3. PubMed ID: 6204368
[TBL] [Abstract][Full Text] [Related]
63. Structural comparison of different antibodies interacting with parvovirus capsids.
Hafenstein S; Bowman VD; Sun T; Nelson CD; Palermo LM; Chipman PR; Battisti AJ; Parrish CR; Rossmann MG
J Virol; 2009 Jun; 83(11):5556-66. PubMed ID: 19321620
[TBL] [Abstract][Full Text] [Related]
64. Epitope diversity of hepatitis B virus capsids: quasi-equivalent variations in spike epitopes and binding of different antibodies to the same epitope.
Harris A; Belnap DM; Watts NR; Conway JF; Cheng N; Stahl SJ; Vethanayagam JG; Wingfield PT; Steven AC
J Mol Biol; 2006 Jan; 355(3):562-76. PubMed ID: 16309704
[TBL] [Abstract][Full Text] [Related]
65. Structural studies on antibody interacting with viruses.
Hewat E; Blaas D
Curr Top Microbiol Immunol; 2001; 260():29-44. PubMed ID: 11443879
[No Abstract] [Full Text] [Related]
66. N9 neuraminidase complexes with antibodies NC41 and NC10: empirical free energy calculations capture specificity trends observed with mutant binding data.
Tulip WR; Harley VR; Webster RG; Novotny J
Biochemistry; 1994 Jul; 33(26):7986-97. PubMed ID: 7517697
[TBL] [Abstract][Full Text] [Related]
67. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines.
Kouiavskaia D; Puligedda RD; Dessain SK; Chumakov K
J Virol Methods; 2020 Feb; 276():113785. PubMed ID: 31765719
[TBL] [Abstract][Full Text] [Related]
68. The crystal structures of complexes formed between lysozyme and antibody fragments.
Bentley GA
EXS; 1996; 75():301-19. PubMed ID: 8765306
[TBL] [Abstract][Full Text] [Related]
69. Production of monoclonal and monospecific antibodies against non-capsid proteins of poliovirus.
Pasamontes L; Egger D; Bienz K
J Gen Virol; 1986 Nov; 67 ( Pt 11)():2415-22. PubMed ID: 2431100
[TBL] [Abstract][Full Text] [Related]
70. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice.
Roivainen M; Montagnon B; Chalumeau H; Murray M; Wimmer E; Hovi T
J Virol; 1990 Feb; 64(2):559-62. PubMed ID: 1688625
[TBL] [Abstract][Full Text] [Related]
71. Differences in conformation of type 3 poliovirus antigenic sites on non-infectious empty particles and infectious virus.
Ferguson M; Minor PD
J Gen Virol; 1990 Jun; 71 ( Pt 6)():1271-4. PubMed ID: 1693661
[TBL] [Abstract][Full Text] [Related]
72. Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus.
Banerjee A; Huang J; Rush SA; Murray J; Gingerich AD; Royer F; Hsieh CL; Tripp RA; McLellan JS; Mousa JJ
Proc Natl Acad Sci U S A; 2022 Jun; 119(25):e2203326119. PubMed ID: 35696580
[TBL] [Abstract][Full Text] [Related]
73. Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1.
Minor PD; Ferguson M; Katrak K; Wood D; John A; Howlett J; Dunn G; Burke K; Almond JW
J Gen Virol; 1990 Nov; 71 ( Pt 11)():2543-51. PubMed ID: 1701474
[TBL] [Abstract][Full Text] [Related]
74. Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.
Evans DM; Minor PD; Schild GS; Almond JW
Nature; 1983 Aug 4-10; 304(5925):459-62. PubMed ID: 6192344
[TBL] [Abstract][Full Text] [Related]
75. Structural basis for recognition of CD20 by therapeutic antibody Rituximab.
Du J; Wang H; Zhong C; Peng B; Zhang M; Li B; Huo S; Guo Y; Ding J
J Biol Chem; 2007 May; 282(20):15073-80. PubMed ID: 17395584
[TBL] [Abstract][Full Text] [Related]
76. Contacts between influenza virus N9 neuraminidase and monoclonal antibody NC10.
Lee JT; Air GM
Virology; 2002 Sep; 300(2):255-68. PubMed ID: 12350356
[TBL] [Abstract][Full Text] [Related]
77. Structural studies on viral escape from antibody neutralization.
Bizebard T; Barbey-Martin C; Fleury D; Gigant B; Barrère B; Skehel JJ; Knossow M
Curr Top Microbiol Immunol; 2001; 260():55-64. PubMed ID: 11443881
[No Abstract] [Full Text] [Related]
78. Electron microscopic examination of the reactivity of three kinds of neutralizing antibodies with H particles of poliovirus.
Taniguchi K; Urasawa S; Urasawa T
Microbiol Immunol; 1983; 27(7):645-8. PubMed ID: 6195513
[No Abstract] [Full Text] [Related]
79. High-resolution asymmetric structure of a Fab-virus complex reveals overlap with the receptor binding site.
Goetschius DJ; Hartmann SR; Organtini LJ; Callaway H; Huang K; Bator CM; Ashley RE; Makhov AM; Conway JF; Parrish CR; Hafenstein SL
Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34074770
[TBL] [Abstract][Full Text] [Related]
80. Capsid antibodies to different adeno-associated virus serotypes bind common regions.
Gurda BL; DiMattia MA; Miller EB; Bennett A; McKenna R; Weichert WS; Nelson CD; Chen WJ; Muzyczka N; Olson NH; Sinkovits RS; Chiorini JA; Zolotutkhin S; Kozyreva OG; Samulski RJ; Baker TS; Parrish CR; Agbandje-McKenna M
J Virol; 2013 Aug; 87(16):9111-24. PubMed ID: 23760240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
